" /> Ascrinvacumab - CISMeF





Preferred Label : Ascrinvacumab;

NCIt synonyms : Anti-Activin Receptor-like Kinase 1 Monoclonal Antibody PF-03446962; Anti-ALK-1 Monoclonal Antibody GT90001; Anti-Activin Receptor-like Kinase-1 Monoclonal Antibody GT90001;

NCIt definition : A human immunoglobulin G2 (IgG2) monoclonal antibody against activin receptor-like kinase-1 (ALK-1; ALK1), with potential anti-angiogenic and antineoplastic activities. Upon administration, ascrinvacumab targets and binds to ALK-1, and prevents ALK-1 activation by its ligands bone morphogenetic protein 9 (BMP) 9 and BMP10. This prevents ALK-1-mediated endothelial cell signaling and the activation of transforming growth factor-beta (TGF-beta)/TGF-beta receptor I (ALK-5) signaling. This inhibits tumor blood vessel growth, reduces blood flow and angiogenesis and leads to an inhibition of tumor cell proliferation and modulation of the tumor microenvironment (TME). ALK-1, a member of the transforming growth factor beta (TGF-b) type I receptor family, is overexpressed on endothelial cells in a variety of tumor cell types and increases endothelial cell proliferation and migration.;

UNII : 716FQ5REVO;

CAS number : 1463459-96-2;

Molecule name : PF-03446962; GT-90001; GT 90001; PF 03446962;

Details


You can consult :


Nous contacter.
13/08/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.